With an estimated 92 percent survival price at three years.

Responses were long lasting for a median of 23 weeks with the longest responding individual in remission much longer than 40 weeks, with an estimated 92 percent survival price at three years. The primary unwanted effects were hematologic with 89 percent of patients developing grade 3-4 neutropenia, which was managed with development factor administration. No patient developed congestive heart failing with no grade 3-4 cardiac unwanted effects observed. The authors concluded the FPD-R regimen was well-tolerated and active in patients with relapsed or refractory INHL highly. ‘This study further adds to the proof substantial anti-tumor activity for pixantrone in past due stage lymphoid malignancies,’ said Jack W.The Daily Health Plan Report is published for Kaisernetwork.org, a free support of The Henry J. Kaiser Family Foundation. Copyright 2009 Advisory Panel Kaiser and Company Family Foundation. All rights reserved.. Celator granted U.S. Patent covering CombiPlex technology platform Celator Pharmaceuticals today announced america Patent and Trademark Office issued U.S Patent No. 7,850,990. This patent increases the intellectual real estate surrounding Celator’s innovative technology systems and products.S. Patent No. CombiPlex is a unique approach using medication carriers to deliver synergistic ratios of medication combinations for the treatment of cancer.